Therapeutic category of drugs in Japan [BR:br08301]
6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D12269  Nirmatrelvir and ritonavir
Drug groups [BR:br08330]
Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12269  Nirmatrelvir and ritonavir
Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D12269  Nirmatrelvir and ritonavir
Metabolizing enzyme inhibitor
  DG02852  CYP3A/CYP3A4 inhibitor
   D12269  Nirmatrelvir and ritonavir
Drug classes [BR:br08332]
Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12269  Nirmatrelvir and ritonavir
Antimicrobials [BR:br08307]
Antivirals
  Polyprotein cleavage inhibitor
   SARS-CoV 3C protease inhibitor
    D12269  Nirmatrelvir and ritonavir <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D12269
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D12269
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D12269
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D12269
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D12269